ArticleCureus2026
A Retrospective Real-World Multicenter Study of the Efficacy and Safety of Desidustat in Chronic Kidney Disease-Related Anemia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) often leads to a relative deficiency of erythropoietin (EPO), resulting in anemia. Exogenous erythropoietin analogs are commonly used to address this deficiency. Desidustat, a recently approved hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), enhances endogenous EPO production. This study evaluates the multicenter outcomes of desidustat in treating CKD-induced anemia. METHODOLOGY: This retrospective analysis included patients with CKD-induced anemia who received desidustat. Patients were followed up at one month, two months, and six months post-treatment initiation. Oral or intravenous (IV) iron was administered based on iron depletion status. Dosage adjustments, therapy compliance, hemoglobin (Hb) levels, and safety parameters were assessed at each follow-up.
resultsThe study included 517 patients with CKD-induced anemia, comprising 39.38% (204) male patients and 60.61% (313) female patients, with a mean age of 57.86 ± 14.24 years. Comorbid conditions included diabetes mellitus (44.29%, 229 patients) and hypertension (61.31%, 317 patients). The majority of patients (88.18%, 456 patients) received desidustat 100 mg thrice weekly. Hemoglobin levels increased from a baseline mean of 9.11 ± 1.38 g/dL to 9.83 ± 1.52 g/dL at follow-up 1, 10.10 ± 1.59 g/dL at follow-up 2, and 10.13 ± 1.74 g/dL at follow-up 3 (p < 0.005), reflecting sustained improvements of 9.13% (0.72 g/dL), 12.05% (0.99 g/dL), and 12.39% (1.02 g/dL) from baseline, respectively. Both dialysis-dependent and pre-dialysis patients showed a consistent rise in Hb levels from baseline, with a numerically greater increase observed in the pre-dialysis group, likely due to better residual kidney function. The treatment was generally well-tolerated, with mild adverse events (AEs) such as constipation and throat pain, which did not require discontinuation of therapy.
conclusionDesidustat is a safe and effective oral therapy for CKD-induced anemia, demonstrating consistent Hb increases in both dialysis and pre-dialysis patients. Its oral administration route enhances usability, particularly in tropical conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.